ALISO VIEJO, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCQB:CNSO)
CNS Response has been named a Finalist for the Innovations in Healthcaresm Award by the Adaptive Business Leaders Organization (ABL), a healthcare CEO organization focused on growing great companies. The ABBY awards, selected from a pool of top national organizations, recognize innovative approaches, medical devices, IT and telecom solutions that improve the delivery and quality of healthcare, while lowering its cost.
"CNS Response addresses a major health issue for a significant portion of our population who wrestle with mental health issues," said ABL President Mimi Grant. "CNS' PEER Online solution impressed the judges on ABL's Finalists Selection Committee that it was not only innovative, but has significant clinical and financial metrics that prove their service is reducing the cost of providing quality care. Increasingly, it will be innovative companies, like CNS Response, that will not only win ABBY Awards, but will be big winners as the healthcare industry shifts from 'volume to value.'"
Three ABBY Award Winners will be chosen by secret ballot following live presentations made by the chief executives of the nine Finalist organizations at the 16th annual Awards event on October 21, 2015. Past Innovations in Healthcaresm Award winners include Daniel Kraft, MD, Medicine and Neuroscience Chair, Singularity University, Steve Case of Revolution Health and Patrick Soon-Shiong, MD, CEO of NantWorks.
About CNS Response Inc.
CNS Response (www.cnsresponse.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company's Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The objective of PEER Online is to reduce trial and error pharmacotherapy, which is the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more about PEER can contact CNS Response representatives at PEERinfo@cnsresponse.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
CONTACT: Media Relations: Lauren Jenkins Scoutcomms 1-877-565-3323 email@example.com